Milbemycin Oxime And Praziquantel

Verify with FDA CVM →

39 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
39
Total Reports
2
Deaths Reported
510.0%
Death Rate

Active Ingredients

Milbemycin Oxime And Praziquantel

Administration Routes

OralUnknown

Species Affected

Dog 39

Most Affected Breeds

Retriever - Labrador 8
Collie - Border 4
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 3
Dachshund (unspecified) 3
Terrier - Jack Russell 2
Retriever - Golden 2
Beagle 2
Boxer (German Boxer) 2
Mixed (Dog) 1
Maltese 1

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 11
Vomiting 8
Lethargy (see also Central nervous system depression in 'Neurological') 5
Diarrhoea 5
Inappetence 4
Lethargy (see also Central nervous system depression in Neurological) 4
Medication error NOS 3
Panting 2
Pustules 2
Not eating 2
Itching 2
Elevated renal parameters 2

Outcome Breakdown

Recovered/Normal
14 (35.9%)
Ongoing
14 (35.9%)
Outcome Unknown
9 (23.1%)
Died
2 (5.1%)

Data Summary

Metric Value
Total adverse event reports 39
Reports involving death 2
Case-fatality rate (reported events) 510.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Milbemycin Oxime And Praziquantel Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 39 adverse event reports referencing Milbemycin Oxime And Praziquantel, including 2 reports in which the animal died — a 510.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Milbemycin Oxime And Praziquantel. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Milbemycin Oxime And Praziquantel reports are Dog (39 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (8), Collie - Border (4), Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Milbemycin Oxime And Praziquantel are Lack of efficacy (endoparasite) - heartworm (11), Vomiting (8), Lethargy (see also Central nervous system depression in 'Neurological') (5), Diarrhoea (5). Of the 39 reports with a coded outcome, Recovered/Normal is the leading category at 35.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Milbemycin Oxime And Praziquantel.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial